𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin

✍ Scribed by Yuko Inoue; Naoki Hiramatsu; Tsugiko Oze; Takayuki Yakushijin; Kiyoshi Mochizuki; Kazuto Fukuda; Eiji Mita; Yoshimichi Haruna; Atsuo Inoue; Yasuharu Imai; Atsushi Hosui; Takuya Miyagi; Yuichi Yoshida; Tomohide Tatsumi; Shinichi Kiso; Tatsuya Kanto; Akinori Kasahara; Tetsuo Takehara; Norio Hayashi


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
347 KB
Volume
83
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Previous reports demonstrated that amino acid (aa) substitutions in the hepatitis C virus (HCV) core protein are predictors of non‐virological responses to pegylated interferon (Peg‐IFN) and ribavirin combination therapy. The aim of this study was to investigate the impact of core aa substitutions on viral kinetics during the treatment and relapse after the treatment. The 187 patients with HCV genotype 1 enrolled in this study were categorized into four groups according to core aa substitution patterns: double‐wild group (n = 92), Arg70/Leu91; 70‐mutant group (n = 42), Gln70/Leu91; 91‐mutant group (n = 31), Arg70/Met91; and double‐mutant group (n = 22), Gln70/Met91. The relationship between the core aa substitutions and the virological response was examined. Multivariate logistic regression analyses showed that substitution at aa 70 was significantly associated with a poor virological response during the first 12 weeks (decline of <1 log from baseline at week 4, <2 log at week 12), and substitution at aa 91 was significantly associated with detectable HCV RNA at week 24. With respect to relapse, only the ribavirin exposure (odds ratio (OR), 0.77; 95% confidence interval (CI), 0.60–0.98) and HCV RNA disappearance between weeks 13 and 24 (OR, 23.69; 95% CI, 5.44–103.08) were associated independently with relapse, with no correlation being found with the core aa substitutions and relapse. In conclusion, the results showed that core aa substitutions can be strong predictive factors at pretreatment of the non‐response, but not for relapse, for virological responders with HCV RNA disappearance during treatment. J. Med. Virol. 83:419–427, 2011. © 2011 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Amino acid substitutions in the hepatiti
✍ Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hiromi Yatsuji; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 1 views

## Abstract Substitution of amino acid (aa) 70 and 91 in the core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferon (PEG‐IFN)/ribavirin combination therapy, but its impact on triple therapy of telaprevir/PEG‐IFN/ribavirin is not clear. The aims of this s

Influence of amino-acid polymorphism in
✍ Mariko Kobayashi; Norio Akuta; Fumitaka Suzuki; Tetsuya Hosaka; Hitomi Sezaki; M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB 👁 2 views

The substitution of amino acid (aa) 70 of arginine for glutamine and/or that of aa91 of leucine for methionine in the core protein in patients infected with hepatitis C virus (HCV) genotype 1b is associated with a poor response to pegylated interferon and ribavirin. Factors influencing these substit

Amino acid substitution in hepatitis C v
✍ Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hiromi Yatsuji; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

Genetic variation near the IL28B gene and substitution of amino acid (aa) 70 and 91 in the core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferon (PEG-IFN)/ribavirin combination therapy, but its impact on triple therapy of telaprevir/PEG-IFN/ribavirin is

Impact of genetic polymorphisms near the
✍ Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Takahisa Kawaguchi; Yoshiki Mur 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 411 KB 👁 1 views

## Abstract It has been reported that genetic polymorphisms near the __IL28B__ gene or amino acid substitutions in hepatitis C virus (HCV) core protein are associated with the clinical outcome of peginterferon (PEG‐IFN) and ribavirin combination therapy. The impact of these factors on the pure sens

Amino acid substitutions in the hepatiti
✍ Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hiromi Yatsuji; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

## Abstract Previous studies provided a direct experimental evidence for the contribution of HCV core protein in the development of insulin resistance (IR), but the clinical impact of HCV core region on IR is still not clear. The present study evaluated the impact of Amino acid (aa) substitutions o

A matched case-controlled study of 48 an
✍ Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hiromi Yatsuji; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

## Abstract Substitution of amino acid (aa) 70 and 91 in the core region of HCV genotype 1b is a useful pretreatment predictor of efficacy of 48‐week peginterferon (PEG‐IFN) plus ribavirin (RBV) therapy. Here, we determined the efficacy of 72‐week PEG‐IFN/RBV and the predictive factors to such ther